{
    "type": "ETP",
    "ucits": false,
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage",
        "Synthetic replication via swaps",
        "Embedded derivatives",
        "Counterparty risk",
        "Daily leverage reset and compounding effects",
        "High risk rating (7/7)",
        "Collateralized swap exposure"
    ],
    "classification": "complex",
    "supporting_data": "The GraniteShares 3x Short Moderna Daily ETP Securities is an exchange traded product that seeks to replicate -3 times the daily performance of Moderna via a swap with Natixis as the swap provider. This product uses synthetic replication through total return swaps, which introduces counterparty and collateral risks that are difficult for retail investors to understand. The product is leveraged at 3x inverse exposure, with daily reset of leverage causing compounding effects that increase complexity. It carries a highest risk class (7/7) and is collateralized but still exposes investors to counterparty risk. The product is not UCITS compliant and is explicitly described as 'not simple and may be difficult to understand,' consistent with MiFID II criteria for complex instruments. According to MiFID II Article 57 and ESMA guidelines, such use of embedded derivatives, leverage, synthetic replication, and complex payoff profiles mandates classification as complex. The productu2019s structure, risks, and payoff profile are not straightforward for retail investors with basic knowledge, requiring an appropriateness assessment under MiFID II."
}